Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Farmington Hills Clinical Site 126
mi
from
Farmington Hills, MI
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Farmington Hills Clinical Site 126
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Lebanon Clinical Site 115
mi
from
Lebanon, NH
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Lebanon Clinical Site 115
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Albuquerque Clinical Site 106
mi
from
Albuquerque, NM
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Albuquerque Clinical Site 106
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Rochester Clinical Site
mi
from
Rochester, NY
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Rochester Clinical Site
mi
from
Rochester, NY
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Charlotte Clinical Site 125
mi
from
Charlotte, NC
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Charlotte Clinical Site 125
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Raleigh Clinical Site 103
mi
from
Raleigh, NC
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Raleigh Clinical Site 103
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Akron Clinical Site 112
mi
from
Akron, OH
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Akron Clinical Site 112
mi
from
Akron, OH
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Philadelphia Clinical Site 120
mi
from
Philadelphia, PA
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Philadelphia Clinical Site 120
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Knoxville Clinical Site 134
mi
from
Knoxville, TN
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Knoxville Clinical Site 134
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Round Rock Clinical Site 107
mi
from
Round Rock, TX
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Round Rock Clinical Site 107
mi
from
Round Rock, TX
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Brugge Clinical Site 203
mi
from
Brugge,
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Brugge Clinical Site 203
mi
from
Brugge,
Click here to add this to my saved trials
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated:  7/21/2015
Clinical Research Facility
mi
from
Phoenix, AZ
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated: 7/21/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated:  7/21/2015
Clinical Research Facility
mi
from
Atlanta, GA
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated: 7/21/2015
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated:  7/21/2015
Clinical Research Facility
mi
from
Baltimore, MD
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated: 7/21/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated:  7/21/2015
Clinical Research Facility
mi
from
Teaneck, NJ
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated: 7/21/2015
Clinical Research Facility
mi
from
Teaneck, NJ
Click here to add this to my saved trials
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated:  7/21/2015
Clinical Research Facility
mi
from
Gilbert, AZ
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated: 7/21/2015
Clinical Research Facility
mi
from
Gilbert, AZ
Click here to add this to my saved trials
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated:  7/21/2015
Clinical Research Facility
mi
from
Danbury, CT
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated: 7/21/2015
Clinical Research Facility
mi
from
Danbury, CT
Click here to add this to my saved trials
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated:  7/21/2015
Clinical Research Facility
mi
from
Fort Wayne, IN
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated: 7/21/2015
Clinical Research Facility
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated:  7/21/2015
Clinical Research Facility
mi
from
Boston, MA
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated: 7/21/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated:  7/21/2015
Clinical Research Facility
mi
from
Golden Valley, MN
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated: 7/21/2015
Clinical Research Facility
mi
from
Golden Valley, MN
Click here to add this to my saved trials
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated:  7/21/2015
Clinical Research Facility
mi
from
Patchogue, NY
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated: 7/21/2015
Clinical Research Facility
mi
from
Patchogue, NY
Click here to add this to my saved trials
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated:  7/21/2015
Clinical Research Facility
mi
from
Cleveland, OH
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated: 7/21/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated:  7/21/2015
Clinical Research Facility
mi
from
Dayton, OH
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated: 7/21/2015
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated:  7/21/2015
Clinical Research Facility
mi
from
Portland, OR
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated: 7/21/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated:  7/21/2015
Clinical Research Facility
mi
from
Cordova, TN
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated: 7/21/2015
Clinical Research Facility
mi
from
Cordova, TN
Click here to add this to my saved trials
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated:  7/21/2015
Clinical Research Facility
mi
from
Franklin, TN
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated: 7/21/2015
Clinical Research Facility
mi
from
Franklin, TN
Click here to add this to my saved trials
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated:  7/21/2015
Clinical Research Facility
mi
from
Milwaukee, WI
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Status: Enrolling
Updated: 7/21/2015
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Effectiveness of Ankle Foot Orthoses on Gait in Multiple Sclerosis
The Impact of Ankle Foot Orthosis (AFO) on Gait Recovery in Select Individuals With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  8/3/2015
University of Texas Southwestern Medical Center, School of Health Professions
mi
from
Dallas, TX
Effectiveness of Ankle Foot Orthoses on Gait in Multiple Sclerosis
The Impact of Ankle Foot Orthosis (AFO) on Gait Recovery in Select Individuals With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 8/3/2015
University of Texas Southwestern Medical Center, School of Health Professions
mi
from
Dallas, TX
Click here to add this to my saved trials
Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS
Phase II Study of Linoleic Acid in Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/7/2015
University of Rochester
mi
from
Rochester, NY
Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS
Phase II Study of Linoleic Acid in Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/7/2015
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Cognitive-behavior Therapy for MS-Related Chronic Pain
Cognitive-behavior Therapy for MS-Related Chronic Pain
Status: Enrolling
Updated:  8/25/2015
VA Connecticut Health Care System
mi
from
West Haven, CT
Cognitive-behavior Therapy for MS-Related Chronic Pain
Cognitive-behavior Therapy for MS-Related Chronic Pain
Status: Enrolling
Updated: 8/25/2015
VA Connecticut Health Care System
mi
from
West Haven, CT
Click here to add this to my saved trials
Cognitive-behavior Therapy for MS-Related Chronic Pain
Cognitive-behavior Therapy for MS-Related Chronic Pain
Status: Enrolling
Updated:  8/25/2015
VA Medical Center, Jamaica Plain Campus
mi
from
Boston, MA
Cognitive-behavior Therapy for MS-Related Chronic Pain
Cognitive-behavior Therapy for MS-Related Chronic Pain
Status: Enrolling
Updated: 8/25/2015
VA Medical Center, Jamaica Plain Campus
mi
from
Boston, MA
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840041
mi
from
Phoenix, AZ
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840041
mi
from
Phoenix, AZ
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840209
mi
from
Tucson, AZ
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840209
mi
from
Tucson, AZ
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840033
mi
from
Loma Linda, CA
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840033
mi
from
Loma Linda, CA
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840034
mi
from
Modesto, CA
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840034
mi
from
Modesto, CA
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840090
mi
from
Fort Collins, CO
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840090
mi
from
Fort Collins, CO
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840011
mi
from
Fairfield, CT
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840011
mi
from
Fairfield, CT
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840013
mi
from
Maitland, FL
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840013
mi
from
Maitland, FL
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840230
mi
from
Ocala, FL
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840230
mi
from
Ocala, FL
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840022
mi
from
Ormond Beach, FL
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840022
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840025
mi
from
Sarasota, FL
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840025
mi
from
Sarasota, FL
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840082
mi
from
St. Petersburg, FL
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840082
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840033
mi
from
Sunrise, FL
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840033
mi
from
Sunrise, FL
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840063
mi
from
Elk Grove Village, IL
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840063
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840064
mi
from
Flossmoor, IL
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840064
mi
from
Flossmoor, IL
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840039
mi
from
Ft Wayne, IN
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840039
mi
from
Ft Wayne, IN
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840012
mi
from
Indianapolis, IN
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840012
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840016
mi
from
Des Moines, IA
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840016
mi
from
Des Moines, IA
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840069
mi
from
Clinton Township, MI
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840069
mi
from
Clinton Township, MI
Click here to add this to my saved trials
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/26/2015
Sanofi-Aventis Investigational Site Number 840253
mi
from
Grand Rapids, MI
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/26/2015
Sanofi-Aventis Investigational Site Number 840253
mi
from
Grand Rapids, MI
Click here to add this to my saved trials